DP24-062 (SIPS), Patient Perspectives on Relabeling and Pathology Reporting for Grade Group 1 Prostate Cancer

University Of California, San Francisco, San Francisco CA

Investigators

Abstract

PROJECT SUMMARY/ABSTRACT There is considerable debate about removing the label of “cancer” from low-grade prostate cancer due to its indolent natural history. A related challenge is the optimal patient-centered presentation of pathology reports in the era of immediate electronic access to clinical results. A critical research gap is the perspective of diverse patient populations on prostate cancer nomenclature and pathology reporting. We will address this gap through 3 key approaches: (1) We will perform qualitative studies of patient perspectives on prostate cancer nomenclature and preferences for a patient-centered pathology report. (2) We will conduct discrete choice experiments to determine the impacts of changes in nomenclature for low-grade prostate cancer. (3) We will conduct a randomized study to test the usefulness of alternative wording in pathology reports and of patient- centered pathology supplements. We will explicitly sample Black, Hispanic, and other men reflecting the broad geographic and socioeconomic diversity of California. All stages of the study will be conducted in English and Spanish. Our multi-disciplinary team is well suited to lead this study with expertise in prostate cancer clinical care, qualitative and quantitative research. Our advisory board includes additional experts in prostate pathology, biostatistics and patients who will be involved in all stages of the research design and public dissemination of results. The expected outcomes of this study will advance the field by studying the optimal prostate cancer nomenclature and pathology reporting in diverse patient populations.